EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence

Spencer S Watson, Anoek Zomer, Nadine Fournier, Joao Lourenco, Manfredo Quadroni, Agnieszka Chryplewicz, Sina Nassiri, Pauline Aubel, Simona Avanthay, Davide Croci, Erik Abels, Marike L D Broekman und 8 weitere

Cancer Cell · 2024-09 · 42 (9) · 1507-1527.e11

DOI: 10.1016/j.ccell.2024.08.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024-09. Verfasst von Spencer S Watson und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausan…. Hauptthemen laut MEDLINE: Glioblastoma, Neoplasm Recurrence, Local, Tumor Microenvironment, Fibrosis. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universite de Lausanne, Netherlands Organisation for Scientific Research, Ludwig Institute for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma recurrence is currently inevitable despite extensive standard-of-care treatment. In preclinical studies, an alternative strategy of targeting tumor-associated macrophages and microglia through CSF-1R inhibition was previously found to regress established tumors and significantly increase overall survival. However, recurrences developed in ∼50% of mice in long-term studies, which were consistently associated with fibrotic scars. This fibrotic response is observed following multiple anti-glioma therapies in different preclinical models herein and in patient recurrence samples. Multi-omics analyses of the post-treatment tumor microenvironment identified fibrotic areas as pro-tumor survival niches that encapsulated surviving glioma cells, promoted dormancy, and inhibited immune surveillance. The fibrotic treatment response was mediated by perivascular-derived fibroblast-like cells via activation by transforming growth factor β (TGF-β) signaling and neuroinflammation. Concordantly, combinatorial inhibition of these pathways inhibited treatment-associated fibrosis, and significantly improved survival in preclinical trials of anti-colony-stimulating factor-1 receptor (CSF-1R) therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaNeoplasm Recurrence, LocalTumor MicroenvironmentFibrosisBrain NeoplasmsAnimalsHumansMiceReceptor, Macrophage Colony-Stimulating FactorCell Line, TumorSignal TransductionXenograft Model Antitumor AssaysTransforming Growth Factor beta

Substanzen

Receptor, Macrophage Colony-Stimulating FactorCSF1R protein, humanTransforming Growth Factor beta

Autor:innen und Institutionen

  • Department of Oncology, University of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausanne, Switzerland; Agora Cancer Research Center Lausanne, 1011 Lausanne,…
  • Agora Cancer Centre, University Hospital Lausanne, 1011 Lausanne, Switzerland; Translational Data Science Facility, SIB Swiss Institute of Bioinformatics, Agora Cancer Research Center Lausanne, 1011 Lausanne, Switzerlan…
  • Proteomics Core Facility, University of Lausanne, 1011 Lausanne, Switzerland.
  • Agora Cancer Centre, University Hospital Lausanne, 1011 Lausanne, Switzerland; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), La…
  • Department of Neurosurgery, Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands; Department of Neurosurgery, Haaglanden Medical Center, 2597 The Hague, the Netherla…
  • Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Förderung

  • Universite de Lausanne
  • Netherlands Organisation for Scientific Research
  • Ludwig Institute for Cancer Research
  • Swiss Cancer League
  • The Brain Tumor Charity

Zitieren

APA

Watson, S. S., Zomer, A., Fournier, N., Lourenco, J., Quadroni, M., Chryplewicz, A., Nassiri, S., Aubel, P., Avanthay, S., Croci, D., Abels, E., Broekman, M. L. D., Hanahan, D., Huse, J. T., Daniel, R. T., Hegi, M. E., Homicsko, K., Cossu, G., Hottinger, A. F., & Joyce, J. A. (2024). Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence. Cancer Cell, 42(9), 1507-1527.e11. https://doi.org/10.1016/j.ccell.2024.08.012

Vancouver

Watson SS, Zomer A, Fournier N, Lourenco J, Quadroni M, Chryplewicz A, et al. Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence. Cancer Cell. 2024;42(9):1507-1527.e11. doi:10.1016/j.ccell.2024.08.012

BibTeX
@article{Watson2024,
  author = {Watson, Spencer S and Zomer, Anoek and Fournier, Nadine and Lourenco, Joao and Quadroni, Manfredo and Chryplewicz, Agnieszka and Nassiri, Sina and Aubel, Pauline and Avanthay, Simona and Croci, Davide and Abels, Erik and Broekman, Marike L D and Hanahan, Douglas and Huse, Jason T and Daniel, Roy T and Hegi, Monika E and Homicsko, Krisztian and Cossu, Giulia and Hottinger, Andreas F and Joyce, Johanna A},
  title = {Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {9},
  pages = {1507--1527.e11},
  doi = {10.1016/j.ccell.2024.08.012}
}
Kostenlos starten →